Risankizumab vs. adalimumab for moderate‐to‐severe plaque psoriasis: a critical appraisal

A. Al‐Janabi, R.B. Warren

Research output: Contribution to journalArticlepeer-review

Original languageUndefined
JournalBritish Journal of Dermatology
Early online date13 Feb 2020
DOIs
Publication statusPublished - 2 Aug 2020

Cite this